leisure time
ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
advertisement
Arch declined to comment on the new fundraising.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Reports of telehealth's death have been greatly exaggerated
Next article： Drug repurposing or repositioning? The language matters
Next article： Drug repurposing or repositioning? The language matters
.png?upscale=true&width=1212&upscale=true&name=vTFET-vaccine-makers-surge-on-bird-flu-fears(3).png)
